Tailored Helicobacter pylori eradication therapy based on prior exposure to Macrolide antibiotics: Prospective study

Tailored Helicobacter pylori eradication therapy based on prior exposure to Macrolide antibiotics: Prospective, pilot study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0007495

Enrollment

Registered

2022-06-30

Start date

2021-10-12

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : After identifying the history of taking macrolide antibiotics within last 5 years by applying for personal treatment information on the HIRA website, the first eradication regimen will be selec

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Who are confirmed H. pylori infection and indicated for eradication, and consent to the provision of personal prescription information

Exclusion criteria

Exclusion criteria: Who do not understand the purpose of the study or do not consent to the examination

Design outcomes

Primary

Measure	Time frame
The eradication rate of standard triple therapy in patients who have not taken macrolides, and the eradication rate of bismuth quadraple therapy in patients who have taken macrolides or have and eradication history	—

Secondary

Measure	Time frame
Antibiotic resistance profile of H. pylori according to macrolide administration history	—

Countries

Korea, Republic of

Contacts

Public ContactJin Hee Noh

Asan Medical Center

mdjh1432@gmail.com+82-2-3010-0086

Outcome results